1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Pyrantel Pamoate / Ivermectin Formulation

Manufacturer or supplier's details
Company : MSD
Address : JL Raya Pandaan KM. 48
Pandaan, Jawa Timur - Indonesia
Telephone : 908-740-4000
Emergency telephone number : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Veterinary product

2. HAZARDS IDENTIFICATION

GHS Classification
Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Central nervous system)
Short-term (acute) aquatic hazard : Category 1
Long-term (chronic) aquatic hazard : Category 1

GHS label elements
Hazard pictograms :  
Signal word : Warning
Hazard statements : H371 May cause damage to organs (Central nervous system) if swallowed.
                  H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
                  H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements : Prevention:
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P273 Avoid release to the environment.

Response:
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.
P391 Collect spillage.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 38.3 %

Other hazards which do not result in classification
None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>&gt;= 30 - &lt; 60</td>
</tr>
<tr>
<td>Glycerine</td>
<td>56-81-5</td>
<td>&gt;= 10 - &lt; 30</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms : May cause damage to organs if swallowed.
and effects, both acute and delayed
Protection of first-aiders
Notes to physician

5. FIREFIGHTING MEASURES

Suitable extinguishing media
    Water spray
    Alcohol-resistant foam
    Carbon dioxide (CO2)
    Dry chemical

Unsuitable extinguishing media
    None known.

Specific hazards during firefighting
    Exposure to combustion products may be a hazard to health.

Hazardous combustion products
    Carbon oxides
    Nitrogen oxides (NOx)
    Sulphur oxides

Specific extinguishing methods
    Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
    Use water spray to cool unopened containers.
    Remove undamaged containers from fire area if it is safe to do so.
    Evacuate area.

Special protective equipment for firefighters
    In the event of fire, wear self-contained breathing apparatus.
    Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures
    Use personal protective equipment.
    Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions
    Discharge into the environment must be avoided.
    Prevent further leakage or spillage if safe to do so.
    Retain and dispose of contaminated wash water.
    Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up
    Soak up with inert absorbent material.
    For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
    Clean up remaining materials from spill with suitable absorbent.
    Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
    Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labelled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-methylenebis[3-hydroxy-2-naphthoic acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>TWA</td>
<td>250 µg/m3 (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Glycerine</td>
<td>56-81-5</td>
<td>NAB (Mist)</td>
<td>10 mg/m³</td>
<td>ID OEL</td>
</tr>
<tr>
<td>Further information: Upper respiratory tract irritation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>0.05 mg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Further information: Skin</td>
<td></td>
<td>Wipe limit</td>
<td>0.5 mg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Combined particulates and organic vapour type
Material: Chemical-resistant gloves

Remarks: Consider double gloving.
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: paste
Colour: yellow
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
Conditions to avoid: None known.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
Skin contact
Ingestion
Eye contact

Acute toxicity:
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method
Acute dermal toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Acute oral toxicity: LD50 (Rat): > 24,000 mg/kg
LD50 (Mouse): > 24,000 mg/kg
LD50 (Dog): 2,000 mg/kg

Glycerine:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity: LD50 (Guinea pig): > 5,000 mg/kg

Ivermectin:
Acute oral toxicity: LD50 (Rat): 50 mg/kg
LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg
Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity: LC50 (Rat): 5.11 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): 406 mg/kg
LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Glycerine:
Species: Rabbit
Result: No skin irritation

Ivermectin:
Species: Rabbit
Result: No skin irritation
**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Glycerine:**
Species: Rabbit
Result: No eye irritation

**Ivermectin:**
Species: Rabbit
Result: Mild eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**Ivermectin:**
Exposure routes: Dermal
Species: Humans
Result: Does not cause skin sensitisation.

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

4,4′-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

**Glycerine:**
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

**Ivermectin:**
Genotoxicity in vitro
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Test system: human diploid fibroblasts
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Glycerine:
Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Ivermectin:
Species : Rat
Application Route : Oral
NOAEL : 1.5 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

Species : Mouse
Application Route : Oral
NOAEL : 2.0 mg/kg body weight
Result : negative
Remarks : Based on data from similar materials

Reproductive toxicity
Not classified based on available information.

Components:

4,4′-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Effects on foetal development
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility and early embryonic develop-
Glycerine:
Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Ivermectin:
Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

STOT - single exposure
May cause damage to organs (Central nervous system) if swallowed.

Components:
Ivermectin:
Target Organs : Central nervous system
Assessment : Causes damage to organs.
SAFETY DATA SHEET

Pyrantel Pamoate / Ivermectin Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue: 2020/03/23</th>
<th>Date of first issue: 2019/09/17</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.2</td>
<td>2020/05/20</td>
<td>4892882-00003</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**STOT - repeated exposure**

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

**Components:**

**Ivermectin:**

| Target Organs: | Central nervous system |
| Assessment:    | Causes damage to organs through prolonged or repeated exposure. |

**Repeated dose toxicity**

**Components:**

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

| Species: | Dog |
| NOAEL:    | 10 mg/kg |
| LOAEL:    | 30 mg/kg |
| Application Route: | Ingestion |
| Exposure time: | 3 d |
| Remarks: | No significant adverse effects were reported |

| Species: | Dog |
| NOAEL:    | 600 mg/kg |
| Application Route: | Oral |
| Exposure time: | 19 d |
| Remarks: | No significant adverse effects were reported |

| Species: | Dog |
| NOAEL:    | 600 mg/kg |
| Application Route: | Oral |
| Exposure time: | 30 d |
| Remarks: | No significant adverse effects were reported |

| Species: | Dog |
| NOAEL:    | 600 mg/kg |
| Application Route: | Oral |
| Exposure time: | 90 d |
| Remarks: | No significant adverse effects were reported |

**Glycerine:**

| Species: | Rat |
| NOAEL:    | 0.167 mg/l |
| LOAEL:    | 0.622 mg/l |
| Application Route: | inhalation (dust/mist/fume) |
| Exposure time: | 13 Weeks |

| Species: | Rat |
| NOAEL:    | 8,000 - 10,000 mg/kg |
| Application Route: | Ingestion |
| Exposure time: | 2 yr |
SAFETY DATA SHEET

Pyrantel Pamoate / Ivermectin Formulation

Version 1.2 Revision Date: 2020/05/20 SDS Number: 4892882-00003 Date of last issue: 2020/03/23 Date of first issue: 2019/09/17

Species: Rabbit
NOAEL: 5,040 mg/kg
Application Route: Skin contact
Exposure time: 45 Weeks

Ivermectin:
Species: Dog
NOAEL: 0.5 mg/kg
LOAEL: 1 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system
Symptoms: Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species: Monkey
NOAEL: 1.2 mg/kg
Application Route: Oral
Exposure time: 2 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 0.4 mg/kg
LOAEL: 0.8 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Fever

Ivermectin:
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination
12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded
Chronic aquatic toxicity : Toxic effects cannot be excluded

Glycerine:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,955 mg/l
Exposure time: 48 h

Toxicity to microorganisms : NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10,000
M-Factor (Chronic aquatic toxicity) : 10,000
Persistence and degradability

Components:

Glycerine:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 92 %
Exposure time: 30 d
Method: OECD Test Guideline 301D

Ivermectin:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50 %
Exposure time: 240 d

Bioaccumulative potential

Components:

Glycerine:
Partition coefficient: n-octanol/water: log Pow: -1.75

Ivermectin:
Bioaccumulation: Bioconcentration factor (BCF): 74
Partition coefficient: n-octanol/water: log Pow: 3.22

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)
Class: 9
Packing group: III
15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health
Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances
Hazardous substances approved for use : Glycerine, Ethanol
Prohibited substances : Not applicable
Restricted substances : Not applicable

Regulation of the Minister of Trade No. 44 of 2009 on Procurement, Distribution and Supervision of Hazardous Materials
Type of Hazardous Materials Restricted to Import, Distribution and Supervision : Not applicable

The components of this product are reported in the following inventories:
DSL : not determined
AICS : not determined
IECSC : not determined

16. OTHER INFORMATION

Further information
Date format : yyyy/mm/dd

Full text of other abbreviations
ID OEL : Indonesia. Occupational Exposure Limits
ID OEL / NAB : Long term exposure limit

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substanc-
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.